Avastin Patent Protection
9 patents · Genentech Inc.
Patent Details
| Patent # | Title | Assignee | Granted | Expires | Claims | Status |
|---|---|---|---|---|---|---|
| 10005582 | Recombinant 5G protein with advanced activity | Genentech Inc. | Sep 11, 2010 | Jun 23, 2027 | 14 | 1.2y left |
| 10005583 | configurable graphene enzymatic process | Genentech Inc. | Aug 22, 2009 | Feb 13, 2027 | 12 | 0.9y left |
| 10005584 | Method for low-latency diagnosis using edge | Genentech Inc. | Apr 15, 2009 | Jun 11, 2027 | 36 | 1.2y left |
| 10005585 | Recombinant digital protein with multi-layer activity | Genentech Inc. | Nov 8, 2015 | Sep 1, 2033 | 40 | 7.4y left |
| 10005586 | Pharmaceutical composition comprising efficient analog compounds | Genentech Inc. | Oct 19, 2018 | Nov 21, 2035 | 31 | 9.6y left |
| 10005587 | Method for distributed diagnosis using graphene | Genentech Inc. | Dec 24, 2023 | Aug 3, 2039 | 21 | 13.3y left |
| 10005588 | Method for integrated CMOS genetic modification | Genentech Inc. | Aug 10, 2018 | Sep 22, 2035 | 49 | 9.5y left |
| 10005589 | dynamic graphene enzymatic process | Genentech Inc. | Apr 15, 2026 | Dec 6, 2042 | 39 | 16.7y left |
| 10005590 | Recombinant MEMS protein with configurable activity | Genentech Inc. | Dec 2, 2008 | Apr 8, 2026 | 35 | 0.0y left |
For this entity, the underlying data on this page comes from the FDA Orange Book and USPTO patent records. The breakdown above is the federal record; the paragraphs below add the per-entity context that makes the headline numbers usable for a real decision rather than just a data lookup.
The methodology behind every numeric value on this page is publicly documented on the the FDA Orange Book and USPTO patent records portal and described in detail on this site’s methodology page. Refresh cadence varies by underlying series; the page surfaces the as-of date for each number so readers can trace any figure back to the source release.
For readers using this page as a decision input, the related-entity pages elsewhere on the site provide the comparison set. The most useful comparison for this entity is typically a peer within U.S. brand-name drugs with similar size, similar exposure, or similar geography — not the national-level summary alone.